Ramachandran Murali - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
VP of Research and Development
Signature
/s/ Ramachandran Murali
Issuer symbol
KAPA
Transactions as of
08 Oct 2025
Net transactions value
$0
Form type
4
Filing time
26 Nov 2025, 18:50:34 UTC
Previous filing
24 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Murali Ramachandran VP of Research and Development C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES /s/ Ramachandran Murali 26 Nov 2025 0001870016

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +152,672 +104% $0.000000 299,529 08 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2 Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting.